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In the context of a declining rate of deaths due to coronary
atherosclerosis, the prevention and management of heart
failure (HF) have an emerging dominant role in cardiovas-
cular care. Prognosis with HF is poor, with about 50%
4-year mortality (1), and definitive treatment is challenging,
related in part to the heterogeneity of causes. Biomarkers
linked to the onset and progression of HF are now of
intense clinical and research interest, with several new
biomarkers related to HF recently approved for clinical use.
In this issue of the Journal, Ho et al. (2) report on one such
biomarker, galectin-3 (Gal-3), and the incidence of new HF
in apparently healthy Americans.
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Gal-3 is a beta-galactoside-binding lectin expressed by
activated macrophages and involved in numerous patholog-
ical processes, including inflammation, tumor growth, and
fibrosis (3). In HF-prone animals, Gal-3 is markedly
up-regulated in decompensated HF (4). Increased Gal-3
expression induces cardiac fibroblasts to proliferate and
deposit type I collagen, contributing to myocardial fibrosis
and adverse remodeling (3). These findings implicate Gal-3
as a possible causal participant in the development of HF.
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GlaxoSmithKline.Gal-3 has been examined as a potential diagnostic and
prognostic marker for HF in humans. First studied in
established HF, higher concentrations of Gal-3 were asso-
ciated with an increased risk for death or recurrent HF
independent of established risk factors in 4 studies ranging
from 232 to 599 patients (5–8). In the largest published
study (n 895), Gal-3 was associated with HF severity and
long-term outcomes, but did not add incrementally to
natriuretic peptides (9). In the context of these data, Gal-3
was cleared for clinical use for prognostication in patients
with established HF. However, Gal-3 does not appear
useful for diagnosis of HF in patients with dyspnea (5).
Gal-3 has also been evaluated as a tool to forecast future
HF. In a case-control study among patients stabilized after
acute coronary syndromes, Gal-3 was associated with the
risk for HF over 2 years (10). In a general population-based
study of 7,968 subjects followed for 10 years, Gal-3 pre-
dicted all-cause death (11). Gal-3 was correlated with age,
sex, and cardiovascular risk factors, but not the risk for
cardiovascular death, leaving open whether Gal-3 is useful to
identify primary prevention candidates at increased risk for
developing HF.
To address this question, Ho et al. (2) measured Gal-3 in
3,353 subjects in the Framingham Offspring Cohort. In
age-adjusted and sex-adjusted analyses, the risk for new HF
over approximately 8 years increased by 28% for each
standard deviation increase in log-transformed Gal-3 con-
centration. This relationship was independent of age, sex,
blood pressure, diabetes, and body mass index. However,
Gal-3 did not substantially improve on the clinical model
for prognostication or discrimination, particularly when
considering B-type natriuretic peptide. The investigators
also examined the relationships between Gal-3 and left
ventricular mass, systolic function, fractional shortening,
and left atrial dimension assessed by echocardiography.
Higher levels of Gal-3 were associated with increased left
ventricular mass but not these other echocardiographic
parameters.
The findings of Ho et al. (2) demonstrate for the first
time a relationship between Gal-3 and future HF in the
general population. Their observations are interesting and
raise several questions.
Does this study establish the mechanism by which Gal-3
is associated with HF? Although experimental results im-
plicate a direct contribution of Gal-3 to cardiac fibrosis and
the unadjusted association with left ventricular mass in Ho
et al’s (2) study is supportive, these data leave open whether
there is a definite link between Gal-3 and cardiac structural
and functional changes in humans. Future studies with
cardiac magnetic resonance imaging or positron emission
tomography may help elucidate these relationships. Nota-
bly, Gal-3 was only weakly correlated with B-type natri-
uretic peptide (r  0.05). The lack of an association with
natriuretic peptides is consistent with Gal-3 acting as an
“early warning” reflecting myocardial changes before the
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Gal-3 is up-regulated in animal models before the develop-
ment of HF (4). Ho et al did not examine other emerging
markers of hemodynamic stress or structural change, includ-
ing midregional proadrenomedullin, ST2, collagen-related
peptides, or high-sensitivity troponin. Also, the investiga-
tors hypothesize that renal dysfunction may mediate Gal-3’s
effects on cardiac remodeling; however, additional investi-
gation should exclude renal function as a mere confounder.
Is Gal-3 sufficiently specific as a biomarker of cardiovas-
cular risk? In this study, Gal-3 appeared to have a stronger
association with death from noncardiovascular than cardio-
vascular causes. Because Gal-3 is common to inflammatory
processes, it is up-regulated in varied fibrotic conditions,
including of the liver, lung, and kidney (3). This lack of
tissue specificity is likely to have implications for consider-
ation of Gal-3 in screening strategies.
Is there sufficient evidence to use Gal-3 for screening of
HF risk? The Ho et al. (2) findings are intriguing and add
support for a link between Gal-3 and the development of
HF in humans, but alone are insufficient to establish a role
for Gal-3 in screening apparently healthy individuals. Gal-3
did not provide substantial incremental information for
predicting HF when renal dysfunction and B-type natri-
uretic peptide were considered; nor were other emerging
biomarkers of HF reported in their study. In addition,
evidence would be needed to determine whether Gal-3 is
helpful for guiding effective preventive interventions. In
patients with systolic HF, lower levels of Gal-3 appear to
identify patients who may benefit from statin therapy (12),
and preliminary data suggest interactions with use of
angiotensin-converting enzyme inhibitors and device ther-
apy. However, as yet, no interactions between Gal-3 and
interventions for HF prevention have been reported. More-
over, the Ho et al. (2) echocardiographic analyses reveal that
Gal-3 did not identify patients with early systolic dysfunc-
tion, for whom the early initiation of an angiotensin-
converting enzyme inhibitor may be useful. Although an
association with HF with preserved ejection fraction is
important, therapeutic options are even more limited for
this syndrome.
Nevertheless, pre-clinical studies suggest that modifica-
tion of Gal-3 levels may play a role in ameliorating the
progression of HF. In a mouse genetic knockout model with
significantly lowered Gal-3 expression, cardiac fibrosis is
reduced and ventricular function improved. In addition, as
described by Ho et al. (2), Gal-3 can be inhibited with
modified citrus pectin, as well as other candidates.
The study by Ho et al. (2) is a step forward in the
assessment of Gal-3 in cardiovascular disease. BecauseGal-3 did not add convincingly to improve discrimination
or reclassification of risk, appropriately, the investigators do
not argue a role for routine screening. However, their
findings lend support to the notion of Gal-3 as a causal factor
in human cardiac disease. Further investigation of Gal-3 may
lead to advances in our understanding of cardiac fibrosis and
remodeling, as well as shine a light toward new therapies for a
challenging and increasingly prevalent disease.
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